Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 76

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 76
---
 and advance its development
programs, the Company intends to continue securing investments. Management anticipates that additional capital will be necessary to fund
its ongoing R&D activities and to explore opportunities for acquiring healthcare or healthcare-related technologies. However, there
are currently no binding commitments for further investment, and there can be no assurance that the Company will secure the required
capital on commercially reasonable terms, or at all.

If sufficient investment cannot be obtained,
the Company may need to implement cost-cutting measures, scale back its R&D activities, or delay certain development programs. Despite
these potential challenges, management and the board of directors believe that the Company’s existing financial resources will
be sufficient to sustain its planned operations for at least the next twelve months.

The consolidated financial statements do not
include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of
liabilities that might be necessary should the Company be unable to continue as a going concern.

<div align='center'>45</div>

Between April and December 2023, the Company
received funds in the aggregate amount of $4,631.25 thousands from qualified investors subscribing into private placement units of the
Company’s securities, where each unit (a “Unit” and collectively the “Units”) is comprised of (i) two (2)
shares of the Company’s common stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s
Common Stock exercisable December 31, 2026, at a per share exercise price of $2.40. The price per Unit is $3.20. In consideration thereof,
the private placement investors were issued an aggregate of 2,894,532 of the Company’s Common Stock and warrants to purchase an
additional 1,447,266 shares of Common stock.

At present, no warrants have been exercised.
Based on our current plans, we believe that with the net proceeds of our private placement offerings, we will have sufficient cash resources
to fund our operations and business plan at least through the next twelve months. Our ongoing operations through the conduct of the clinical
trial program will continue to consume cash resources without generating revenues. There is no guarantee that will be successful in obtaining
an adequate level of financing needed for its long-term research and development activities on commercially reasonable terms.

Foreign Exchange Risks

Our financial statements
are denominated in U.S. dollars and financial results are denominated in U.S. dollars, while a significant portion of our business is
conducted